The latest price target for Forte Biosciences (NASDAQ:FBRX) was reported by Chardan Capital on December 4, 2024. The analyst firm set a price target for $64.00 expecting FBRX to rise to within 12 months (a possible 230.92% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Forte Biosciences (NASDAQ:FBRX) was provided by Chardan Capital, and Forte Biosciences maintained their buy rating.

The last upgrade for Forte Biosciences Inc happened on April 8, 2024 when Ladenburg Thalmann raised their price target to $2.75. Ladenburg Thalmann previously had a neutral for Forte Biosciences Inc.

There is no last downgrade for Forte Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Forte Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Forte Biosciences was filed on December 4, 2024 so you should expect the next rating to be made available sometime around December 4, 2025.

While ratings are subjective and will change, the latest Forte Biosciences (FBRX) rating was a maintained with a price target of $64.00 to $64.00. The current price Forte Biosciences (FBRX) is trading at is $19.34, which is out of the analyst’s predicted range.